Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment

Chiung-Chyi Shen1,2,3,4,5,6*, Wen-Yu Cheng1,2,7, Chung-Hsin Lee1,8, Xue-Jun Dai9, Ming-Tsang Chiao1, Yea-Jiuen Liang1, Wan-Yu Hsieh1, Tsuo-Fei Mao5, Guo-Shi Lin9, Shou-Ren Chen9, Bai-Shuan Liu10 and Jun-Peng Chen11

Abstract

Background: It has previously been shown that bevacizumab, when added to chemotherapy, improved overall survival in several cancers. In glioblastoma multiforme (GBM), bevacizumab increased progression-free survival and it is widely used for tumor recurrence, though it has failed to improve overall survival (OS) in controlled trials. However, an effective biomarker for predicting the prognosis of bevacizumab treatment has yet to be identified. This study, therefore, aimed to retrospectively analyze the polymorphisms of p53 codon 72 and the clinical characteristics of GBM specimens from Taiwanese patients.

Methods: The polymorphisms of p53 codon 72 in 99 patients with GBM treated at Taichung Veterans General Hospital in Taiwan from 2007 to 2017 were analyzed using direct DNA sequencing and PCR-RFLP analysis.

Results: We found that among these GBM patients, the distribution of codon 72 polymorphisms was 28.3% for proline homozygotes (Pro/Pro), 38.4% for arginine homozygotes (Arg/Arg), and 33.3% for proline/arginine heterozygotes (Pro/Arg). Although the polymorphisms of p53 codon 72 were not directly associated with the overall survival of GBM, both the Arg/Arg and Arg/Pro genotypes were associated with significant benefits in terms of overall survival in patients treated with CCRT plus bevacizumab compared to patients treated with CCRT alone.

Conclusions: This pilot study suggests that both the Arg/Arg and Arg/Pro genotypes of p53 codon 72 polymorphism may have value as independent prognostic or predictive parameters for bevacizumab treatment response and failure. Relatedly, the results of the study further demonstrate the utility of stratifying GBM patients according to bevacizumab sensitivity.

Keywords: Glioblastoma multiforme, Polymorphism, p53, Codon 72, Bevacizumab, SNP
Background
The tumor suppressor gene p53 is a core gene in the p53 signaling pathways, including those that guard the genome and prevent tumorigenesis by promoting cell growth arrest, DNA repair, senescence, and cell death, in addition to modulating autophagy and cancer metabolism [1, 2]. Hence, p53 is one of the most frequently mutated genes in human malignancies, with p53 mutations having been found in more than 50% of human cancers [3]. In addition to mutations that inactivate the functions of p53, many single nucleotide polymorphisms (SNPs) have been identified in the p53 gene that also influence the molecular function of the p53 protein as the guardian of the genome [4].

The p53 mutation database of the International Agency for Research on Cancer (IARC) lists 29 common polymorphisms in the non-coding region of TP53 [5]. Among these SNPs of the p53 gene, one well-known SNP that occurs on codon 72, the Arg72Pro polymorphism (rs1042522), is common. The p53 codon Arg72Pro is a C/G variation upstream of the p53 gene on human chromosome 17p13. According to past studies, the Pro72 variant (the Pro/Pro variant of p53 codon 72) protein encourages faster apoptosis and repression alteration more competently than the Pro72 protein [7]. Relatedly, while many case-control studies have investigated the association between p53 codon 72 Arg/Pro polymorphisms and glioma risk, those studies have provided inconsistent findings.

Bevacizumab is a humanized monoclonal immunoglobulin G1 antibody that is also the first antiangiogenic cancer therapy agent that has been used as a monotherapy or in combination with other anti-cancer agents for various types of cancer [8]. The possible mechanism by which bevacizumab achieves its effects is by targeting VEGF-A to prevent its interaction with VEGFR-1 and VEGFR-2 [9]. At present, bevacizumab is approved by the FDAs of more than 60 countries for the treatment of recurrent or progressive glioblastoma multiforme (GBM, WHO grade IV), although an effective biomarker for predicting the progression of bevacizumab treatment has yet to be found. In Taiwan, bevacizumab alone is used to treat adult patients with relapsed GBM who have undergone standard radiation therapy and have failed chemotherapy with temozolomide.

We therefore sought, in the present study, to determine the significance and context for appropriate clinical applications of p53 codon 72 variant polymorphisms based on specimens from 99 cases of GBM, in particular to determine whether there are any associations between p53 codon 72 polymorphisms and the effects of bevacizumab treatment for GBM. Our final goal was to find a novel angiogenesis-related predictive biomarker, of response to bevacizumab in recurrent GBM.

Methods
P53 polymorphism analysis by PCR amplification and direct sequencing
The extraction of genomic DNA was performed from frozen tumor tissues. For the p53 polymorphism analysis, target sequences (i.e., genomic DNA containing intron fragments) were amplified by polymerase chain reaction (PCR) using the following primer pairs: P1-F (5′- CCCACT TTTCTCTTGTGACG-3′), P1-R (5′- CACTGACAGG AACGCAAAGG-3′), P2-F (5′- AagCTCCTTGAgTTA gACg-3′), P2-R (5′- gTTATAggACAAATAAgC-3′), P3-F (5′- TgCAgTGAgCTAgATCAACg-3′), P3-R (5′- AA ACAGTCAAgAAgAAACggC-3′), P4-F (5′- CA CAaGg ATCAcTTgAAACCc-3′), P4-R (5′- CAggCCAAcTTg TTCAgTgg-3′). The DNA sequences of the PCR products were then determined using a DNA autosequencer (GeneAmp PCR System 2700 Thermal cycler; Applied Biosystems) (N = 76 cases of GBM) and a standard procedure [10]. All the heterozygous p53 polymorphisms were confirmed by direct sequencing of both strands.

We also analyzed an additional 23 GBM patients for p53 codon 72 using the polymerase reaction-restriction fragment length polymorphism (PCR-RFLP) method [11] due to its low cost and speed. Brief description of the method: a 366-bp fragment of the p53 gene was amplified from GBM genomic DNA using the forward primer (p53R72P-F) 5′-GTcCTCTGACGTCCTT TcACCCATCTAC-3′ and reverse primer (p53R72P-R) 5′-GGgATAcGGCCAGGACCTGAAGTcCT-3′. (Supplementary Data Fig. S2) The PCR reaction mixture was pretreated at 95 °C for 10 min followed by 35 cycles at 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 1 min. The final extension was conducted at 72 °C for 7 min. Enzyme digestion was conducted using 20 units of BstUI (New England Biolabs, Beverly, MA) and 10 μL of PCR product, and with a final volume of 20 μL. The reaction was incubated at 60 °C for 2 h, electrohoresed with 2% agarose gel and stained with ethidium bromide. The Arg/Arg homozygote of the p53 codon 72 variant was cleaved using BstUI and yielded 215- and 151-bp bands (Fig. 2e). The Pro/Pro homozygote was not cleaved using BstUI and yielded a single 366-bp band. The Arg/Pro heterozygote contained all three bands (366, 215, and 151 bp) following restriction digestion. In these specimens, we have chosen randomly 7 samples and confirmed the types of p53 codon 72 variant using DNA sequencing. The final all results of the p53 codon 72 variant were consistent (data not shown).
Patients and follow-up
A total of 99 patients diagnosed with glioblastomas who underwent macroscopic total or near-total tumor resection at the Department of Minimally Invasive Skull Base Neurosurgery, Neurological Institute, Taichung Veterans General Hospital from 2007 to 2017 comprised the primary study cohort. All GBM patients were treated with surgical resection, received concurrent chemoradiotherapy with temozolomide (TMZ: 75 mg/m²/d) (CCRT), and adjuvant TMZ (150–200 mg/m²/d). Bevacizumab (10 mg/kg intravenously every 2 weeks until progression) was only used in patients with recurrent GBM. This retrospective review was exempt from the requirement for informed consent. The validation cohort consisted of 99 cases selected from the primary cohort based on the following criteria: (1) available follow-up data and samples and (2) a post-operative survival time of more than 1 month. This study was reviewed and approved by the committee on ethics of the Institutional Review Board of Taichung Veterans General Hospital. The obtained samples were frozen immediately after surgery with prior consent from the patients. The overall survival (OS) time was identified as the time from the operation to the date of death or censored at the date of the last follow-up examination. All the patients in the validation cohort were evaluated using the Karnofsky Performance Scale (KPS). The study end date was 31 March 2020.

Statistical analysis
The demographic data was presented as the number (percentage) of patients for categorical variables and compared using the chi-squared test or Fisher’s exact test. OS outcomes were estimated using the Kaplan-Meier method, and the differences in survival were determined using the log-rank test. All data were analyzed using the Statistical Package for Social Sciences (IBM SPSS version 22.0).

Results
Sequence comparison of p53 polymorphism variants in GBM specimens by direct DNA sequencing
To understand the genomic DNA mutant status of the p53 gene in the GBM specimens, p53 gene detection was performed by PCR followed by direct DNA sequencing. Figure 1a and b show the schematic diagram of the genomic p53 gene and the localization of PCR products in the p53 gene, respectively. According to the genomic DNA reference sequence of p53 (association number: NC_000017.10) from the National Center for Biotechnology Information (NCBI) database, we designed four pairs of primers, namely, the P1 (expected PCR DNA fragment size: 764 bps), P2 (expected PCR DNA fragment size: 645 bps), P3 (expected PCR DNA fragment size: 983 bps) and P4 (expected PCR DNA fragment size: 1009 bps) pairs, in order to analyze the over 3000 nucleotides of the p53 gene (Fig. 1a). Electropherograms of each PCR product size are shown in Fig. 1b. Among these PCR products, P2 and P3 covered the most common hotspots of p53 mutation (exons 5–8) [12, 13]. In conducting the DNA sequencing of dozens of GBM specimens and cell lines, we found 6 abnormal single nucleotide polymorphisms (SNPs) or losses of nucleotides, and we then gave each of them a sequence coding number (1–6). These numbers were 1. SNP38, 2. Loss of 16-nucleotides, 3. 11,299, 4. Codon 72, 5. SNP72, and 6. SNP92, respectively. Among them, Nos. 1–4 are located at the P1 PCR product (between exons 2–4 of the p53 gene), and Nos. 5–6 are located at the P3 PCR product (between the 7th intron of the p53 gene) (Fig. 1a). The detailed sequences and localizations of these abnormal points are shown in Fig. 1a, c, and d.

The types of these abnormal points are shown in Fig. 2. Both the No. 1 SNP38 and No. 4 Codon 72 are located at the P1 PCR product. More specifically, the No. 1 SNP38 is located in the 38th nucleotide of the 2nd intron between exons 2 to 3 (association number: NC_000017.10, no. 11117, single nucleotide polymorphism) (Fig. 1a, c). According to the NCBI provided sequence, this base position is a C nucleotide (CC, homozygote, single peak, Fig. 2a, asterisk). However, in our specimens from various individuals, this position was occupied by a G (GG, homozygote, single peak) or CG (heterozygote, two peaks, Fig. 2a, asterisk). A similar situation of SNPs also exists in the No. 4 codon 72, No. 5 SNP72, and No. 6 SNP92, the differences being due to base substitutions. The focus is the No. 4 codon 72 (rs1042522) of the p53 gene where a single nucleotide polymorphism leads to the expression of a homozygote with arginine (GGC, Arg 72; R72), proline (CCG, Pro 72; P72), or P72/R72 heterozygote residues. However, we made a choice to halt the analysis of the DNA fragments of P2 and P4 because these DNA fragments were found to have no significant anomalies (N = 20, data not shown).

Interestingly, we found that in these four SNPs, a specific nucleotide resulted in certain linkages. For example, if the No. 1 SNP38 of T98G cells was identified as a CC genotype by direct DNA sequencing, the other three SNPs would be identified as follows: the No. 4 codon 72 must be a CC (Pro/Pro; P72; homozygote) genotype, the No. 5 SNP72 must be a TT genotype, and the No. 6 SNP92 must be a GG genotype. If the No. 4 codon 72 of U87 cells was identified as a GG (Arg/Arg; R72; homozygote) genotype by direct DNA sequencing, the other three SNPs would be identified as follows: the No. 1 SNP38 must be a GG genotype, the No. 5 SNP72 must be a CC genotype, and the No. 6 SNP92 must be a TT genotype (Fig. 2a, b). Furthermore, if any one of the above four SNPs was a heterozygote genotype, the other
three SNPs also had to be a heterozygote genotype (Fig. 2a, b), such as a p53 haplotype. These specific coincidences always occur together, and were completely suitable for our DNA sequencing of the GBM specimens (N = 34, data not shown).

In addition, we also analyzed the p53 PIN3 A2 allele (16-bp duplication) at the 3rd intron of the p53 gene, which was the same as the 16-bp (base pairs) duplication polymorphism (rs17878362) [14]. We subsequently gave it a sequence coding No. 2 LO-16 nt. In our GBM specimens, the No. 2 LO-16 nt usual presented with homozygote genotyping (loss of double-strand DNA), which did not result in double peaks in the DNA sequencing of nucleotide No. 11250 (NCBI association number: NC_
Fig. 2 (See legend on next page.)
However, we only detected a few heterozygote genotypes of No. 2 LO-16 nt, with these genotypes resulting in double peaks in the DNA sequencing of nucleotide No. 11265 (NCBI association number: NC_000017.10; Fig. 2d). Most importantly, we found that almost all of the GBM specimens had this loss of 16-bp (Table 1). Interestingly, we also found two kinds of nucleotide repeat elements in the 3rd intron of the p53 gene. One of them just the sixteen base pairs duplication polymorphism (Fig. 2c red sequences of letters and green underlining; Fig. 1c green underlining, green sequences of letters). The other one consists of four of

![Figure 2](image-url)

**Table 1** The correlations among p53 codon 72 variants and various patient characteristics

| Patients (n = 99) | codon 72 (No.4) | p value |
|------------------|-----------------|---------|
|                  | CC (n = 28)     | GG (n = 38) | CG (n = 33) |
| Age (n = 99)     |                 |          |             |
| > 60             | 58 58.59%      | 21 75.00% | 23 60.53%   | 14 (42.4%) |
| ≤ 60             | 41 41.41%      | 7 25.00%  | 15 39.47%   | 19 (57.6%) |
| Gender (n = 99)  |                 |          |             |
| Male             | 43 43.43%      | 13 46.43% | 15 39.47%   | 15 45.45% |
| Female           | 56 56.57%      | 15 53.57% | 23 60.53%   | 18 54.55% |
| Tumor number (n = 99) |             |          |             |
| Solitary         | 78 78.79%      | 20 71.43% | 30 78.95%   | 28 84.85% |
| Multiple         | 21 21.21%      | 8 28.57%  | 8 21.05%    | 5 15.15%  |
| Tumor size (n = 99) |             |          |             |
| > 3 cm           | 12 12.12%      | 6 21.43%  | 2 5.26%     | 4 12.12%  |
| ≤ 3 cm           | 87 87.88%      | 22 78.57% | 36 94.74%   | 29 87.88% |
| Tumor occurrence (n = 99) |         |          |             |
| Primary          | 78 78.79%      | 20 71.43% | 31 81.58%   | 27 81.82% |
| Recurrence       | 21 21.21%      | 8 28.57%  | 7 18.42%    | 6 18.18%  |
| Bevacizumab (n = 99) |             |          |             |
| No used          | 45 45.45%      | 13 46.43% | 21 55.26%   | 11 33.33% |
| Used             | 54 54.55%      | 15 53.57% | 17 44.74%   | 22 66.67% |
| LO-16 nt (n = 76, DNA sequencing) (No. 2; rs17878362) | | |
| Heterozygote loss | 6 (7.9%) | 3 (13.6%) | 0 (0.0%) | 3 (12.5%) |
| Homozygote loss  | 70 (92.1%)     | 19 (86.4%) | 30 (100%) | 21 (87.5%) |
| 11,299 (No.3) (n = 76, DNA sequencing) | | |
| CC               | 65 85.53% | 15 68.18% | 30 100.00% | 20 83.33% |
| CA               | 8 10.53%  | 4 18.18%  | 0 0.00%    | 4 16.67%  |
| AA               | 3 3.95%   | 3 13.64%  | 0 0.00%    | 0 0.00%   |

Chi-squared test: *p < 0.05, **p < 0.001, Statistical significance
the same 9-bp repeat sequences (gggctgggg) localized in this region (Fig. 1c, purple underlining, purple sequences of letters). The DNA repeat positions are likely to be used by the cell as a genome folding map [15]. To explore the available predicted biomarkers of bevacizumab treatment, we also analyzed the GBM tumor tissue status of a series of associated molecular genes, including mutations of the IDH gene and p53 genes, the protein expressions of p53 and hTERT, and the methylated status of MGMT promoter (Supplementary Data Tables 1, 2). Although most of the results indicated no statistically significant association in terms of distribution, the distribution of p53 wild-type status was 75% in the CCRT plus bevacizumab group (Supplementary Data Table 2), suggesting that one possible reason that this group benefited from the addition of bevacizumab was associated with the wild-type of p53 gene.

To further investigate the relationship between the p53 polymorphisms and GBM, we undertook a retrospective cohort study of 99 cases of GBM. We employed the PCR of genomic DNA, using previously designed P1 primers (expected PCR DNA fragment size: 764 bps) and direct DNA sequencing to examine the p53 variants at codon 72. As shown in Table 1, the sex ratio of the analyzed GBM patients from whom the samples were taken was 56.6%: 43.4% (female: male), and the mean age of the patients was 55.6. We found that among these GBM patients, the distribution of codon 72 polymorphism was 28.3% for proline homozygotes (Pro/Pro, P72), 38.4% for arginine homozygotes (Arg/Arg, R72), and 33.3% for proline/arginine heterozygotes (Pro/Arg, P/R 72) (Table 1). The variants of the p53 polymorphisms did not correlate with patient age, patient gender, tumor number, tumor size, tumor occurrence, bevacizumab treatment, or LO-16-nt (p > 0.05) (Table 1). The 99 GBM patients investigated in the study died after a median follow-up of 16.6 months (range 11.31–21.87 months) (Fig. 3a). Next, we tried to evaluate the effects of the p53 codon 72 on the OS of these GBM patients. However, the OS analysis (N = 99) comparing the p53 codon variants did not show any significant results (Fig. 3b), with only a slightly better survival rate found to be associated with both the Arg/Arg and Pro/Arg variants. In addition, we also evaluated the effect of bevacizumab in combination with chemotherapy on the OS of GBM patients. The OS analysis comparing the patients treated with chemotherapy alone (N = 45) to those treated with a combination treatment including bevacizumab (N = 54) indicated that bevacizumab had a significantly positive effect (Fig. 3c). Indeed, in comparison with the concurrent chemoradiotherapy with temozolomide (CCRT) group, the group treated with CCRT plus bevacizumab group showed a significant (log-rank p < 0.001) improvement in median OS from 9 to 25.2 months (Fig. 3c). Our retrospective survey suggested that bevacizumab prolongs the OS of patients with recurrent GBM. However, these results still must be verified by a well-designed prospective randomized control trial.

**Genotype effect on overall survival after bevacizumab treatment**

The overall survival data of all the GBM patients were included in the survival analysis. Based on the log-rank test and Kaplan-Meier survival curve analysis, overall survival was not significantly different between the CCRT group patients and the CCRT plus bevacizumab group patients with the codon 72 Pro/Pro genotype. Although the median survival of the patients treated with CCRT plus bevacizumab was 23.1 months compared to 9.2 months for the group treated with CCRT alone, the difference was not significant (p = 0.497, Fig. 4a). In contrast, in both the Arg/Arg and Pro/Arg genotype groups, the median survival durations of the patients treated with CCRT plus bevacizumab were greatly increased compared to that of the patients treated with CCRT only, with the differences being significant (p < 0.001, Fig. 4b, c). Overall survival was significantly increased in
the CCRT plus bevacizumab treatment cohort among patients with both the Arg/Arg and Pro/Arg genotypes compared to those with the Pro/Pro genotype (Fig. 4). Similarly, in both the Arg/Arg (9.8 months) and Pro/Arg (9.6 months) genotype groups, the median survival duration of progression-free survival (PFS) of the patients treated with CCRT plus bevacizumab were greatly increased compared to the Pro/Pro genotype group (7.7 months) (Supplementary Data Fig. S1b).

To clarify the differences in p53 codon 72 polymorphisms among people of different ethnicities in spite of the lack of a healthy control group, the distribution of the p53 codon 72 polymorphisms in the germline DNA of our patient cohort was compared to data for healthy controls in previously published studies, including healthy controls from the Taiwan population only [16–23], and for global glioma cases from the PubMed database [24–32] (Fig. 5). First, we only analyzed the relevant studies in Taiwan with p53 codon 72 data but did not distinguish the types of diseases. As shown in Fig. 5a, the distribution range for the Pro/Pro genotype of p53 codon 72 was found to be 12.4–32.8% (gray), while the ranges for the Arg/Arg and Arg/Pro genotypes were found to be 9.5–39.5% (blue) and 31.6–66.9% (orange color), respectively. Our data showed that the distribution of the p53 codon 72 genotypes in the GBM samples (Fig. 5a, lane 1) approached and met the expectations for the Taiwan population. Interestingly, among the global glioma cases (Fig. 5b), the distribution range of the Pro/Pro genotype of p53 codon 72 was only 2.2–8.7% in the Caucasian population, excluding India and Brazil, whereas the distribution range of the Pro/Pro genotype of p53 codon 72 in India was close to that in our GBM data, in spite of Indians being affiliated with the Caucasian population.

Although the above data do not prove that p53 codon 72 is a risk factor for glioma, they show an obvious difference in the distribution of p53 codon 72 variant genotypes between Taiwan and Caucasian populations.

**Discussion**

In this study, we only investigated the polymorphisms of p53 codon 72 and the tumor spectrums of Taiwanese patients (total number = 99) with GBM, ignoring the question of whether or not the p53 gene had a mutation in any given case. In investigating the distribution of p53 codon 72 genotypes in our Taiwanese population of GBM patients, we found that the genotypes included Pro/Pro (28.3%), Arg/Arg (38.4%), and Arg/Pro (33.3%) genotypes. The results showed that all the genotypes of p53 codon 72 are not directly associated with the overall survival of GBM patients. However, the addition of bevacizumab treatment significantly prolonged overall survival and progression-free survival compared with those of the patients treated with CCRT alone (Fig. 3c and Supplementary Data Fig. S1). Interestingly, in analyzing the different treatments, we found that the retention of the p53 codon 72 arginine allele in the tumor tissue of both the Arg/Arg homozygous and Pro/Arg heterozygous GBM patients was associated with significantly prolonged overall survival. Such results are very unique and rare. Consequently, the results presented here still require further confirmation in a larger sample of patients.

Glioblastoma multiforme is a multifactorial and complex disease and is closely associated with the interactions between environmental factors and genetic backgrounds. Past studies of the p53 gene have displayed a large amount of information regarding the complexity
of its function in and regulation of the brain tumor process. Mutations in the p53 gene occur frequently in many kinds of cancerous tumors, including brain tumors. More specifically, approximately 10% (of hematopoietic malignancies) to 50–70% of all other human cancers are found to have somatic mutations in the p53 gene [33], with approximately 25% of gliomas carrying mutations in the p53 gene [34]. Not only are the p53 mutants able to attenuate cancer cell responses to radiotherapy; rather, they can also trigger chemoresistance [35, 36], even driving resistance to antiangiogenic therapies targeting the GBM vasculature [37]. Due to other well-known prognostic markers already being in use, we sought to determine the significance and context for appropriate clinical applications of p53 status as a marker in our cohort. Our retrospective analysis results showed that some GBM patients who benefited from bevacizumab treatment were likely to carry the wild-type of the p53 gene (Supplementary Data Tables 1, 2).

In past research about the p53 gene polymorphisms in the non-coding region, the 16-bp duplication polymorphism (rs17878362) within intron 3 has been widely analyzed as a possible cancer susceptibility modifier. The Ins allele variant of the p53 intron 3 16-bp duplication polymorphism is associated with a significantly increased risk of breast cancer [38]. One possible reason for this is that the 16-bp Ins allele (duplication, A2A2) leads to lower level of p53 transcript, suggesting that extra-long polymorphisms are likely to cause an alteration in the processing of messenger RNA (mRNA), to the extent of even being translated into a defective protein, leading to a decrease in the p53-mediated apoptosis of tumor cells [38, 39]. The haplotypes with mutant alleles of the p53 (A2) gene were previously found to be associated with an increased risk for tumorigenesis. Moreover, in a comparison of different population groups, increased cancer risk was associated with A2A2 carrier in Indian, Mediterranean, and Northern European populations but not in the Caucasian population of the United States [40]. Being an A2A2 carrier...
also a high-risk factor for breast and colorectal cancers, but not for lung cancers [40]. In our results, we analyzed the distribution of the genotype (rs17878362) carriers of the duplicated allele and found that those in which a deletion was recorded (A1A1) (92.1%) constituted the most prevalent genotype in the GBM patients, being far more common than those in which an insertion was recorded (A2A1) (7.9%) among heterozygote carriers, while not a single homozygote carrier (A2A2) was found. Although these results were not statistically significant, they still represent the distribution of A2A2 genotypes (rs17878362) in the Taiwanese population and indicate the tumor-specific effects of GBM.

Many case-control studies have investigated the association between p53 codon 72 Pro/Arg polymorphism, but those studies have provided inconsistent findings. Nonetheless, more and more meta-analysis evidence obtained by pooling all the currently available case-control studies to estimate the effect and distribution of p53 codon 72 Arg/Pro polymorphism on cancer susceptibility has indicated that the polymorphism is not associated with overall cancer odds in several populations, including Iranian [41] and Chinese [42] colorectal cancer patients [43]. However, others studies have indicated the opposite, that is, that the polymorphism is associated with increased risk of several malignancies associated with viral infections, including in Caucasian (prostate cancer) [44], European (high-grade glioma; Pro 72) [45], Indian (cervical cancer) [46], Chinese (cervical cancer) [47], and Japanese (hepatocellular carcinoma) populations [48], implying that important ethnic and tumor type differences may exist regarding the cancer susceptibility of p53 codon 72 polymorphisms. Although our data could not show whether a given p53 codon 72 polymorphism is a risk factor, such polymorphisms may have an influence on GBM susceptibility in combination with certain other elements. Also, our data regarding the distribution of genotypes in codon 72 showed various shared and unshared GBM characteristics between Caucasian and Taiwanese patients (Fig. 5). This is the first report on the p53 codon 72 polymorphism spectrum and clinical characteristics of a large series of high-grade Taiwanese glioma patients.

Recent studies regarding the two genetic variants of p53 codon 72 (Pro 72 and Arg 72) have indicated that the two variants have different functional activities in the molecular mechanism. Pro 72 has significantly higher levels of BPDE (benzo[a]pyrene-7,8,9,10-diol epoxide)-induced apoptosis index compared to Arg 72 in primary lymphocytes [49]. The Arg 72 protein encourages (15-fold) faster apoptosis [50] and represses genetic alteration more competently than the Pro 72 protein [7]. Furthermore, cancer patients harboring wild type p53 and Arg 72 genotypes and patients with mutant p53 in combination with Pro 72 genotypes had better response rates, as well as better overall and progression-free survival [51]. Also, the p53 codon 72 variants show different affinities in terms of protein-protein interactions, resulting in a different half-life and phosphorylation of the p53 protein. The phosphorylation at Ser-20 of the p53 protein escapes from degradation by MDM2 (as E3 ubiquitin-protein ligase for p53), leading to stabilization of the p53 protein [52]. A recent study further revealed that both VEGF-A and MMP-9 are significantly elevated in mammary glands from R72 compared to P72 mice in a humanized p53 mouse model, with the R72 mice also showing a significantly higher amount of CD31+ blood vessels [53]. Similarly, increased angiogenesis has been observed in glioma model mice, in which the COX-2 and CCL2 pathways promote gliomagenesis by directly supporting the systemic development of myeloid-derived suppressor cells (MDSC) and their accumulation in the tumor microenvironment, where they limit cytotoxic T lymphocyte infiltration [54]. However, this vicious process can be blocked or slowed down in glioma-bearing COX2-deficient and CCL2-deficient mice, through treatment with COX-2 inhibitors, and through MDSC-mediated immunosuppression [54]. Inferring from this mechanism, it seems likely that the R72 variant that induces angiogenesis and vasodilation is susceptible to treatment with bevacizumab.

In February of 2004, the US FDA approved the use of bevacizumab as a first- or second-line treatment for patients with metastatic carcinoma of the colon or rectum, and since that time, finding effective and suitable cancer biomarkers has been one of the important steps in the treatment of cancers [55]. These biomarkers usually are not only expressed abnormally but are involved in the vital biological processes, including angiogenesis, differentiation, and growth [55]. Several predictive genomic biomarkers for bevacizumab have been identified in various indications, including pH-weighted amine chemical exchange saturation transfer echoplanar imaging [56], soluble carbonic anhydrase IX [57], and apelin/APLN [58], among others, while none has been prospectively validated yet [59]. The lack of any ability to identify patients who will benefit a priori, that is, the absence of a predictive biomarker, means that nearly every patient is treated with the antibody, in spite of not knowing which patients would be more likely to derive any benefit from it. It is interesting that several clinical data have confirmed that bevacizumab has clinically meaningful efficacy and an acceptable safety profile in Asian populations, as well as in global populations [60–62], suggesting our results consistent with previous reporting data.

The severe difficulty of determining the exact effects of different variants is likely to be influenced by their multiple roles within individual microenvironments as compared with tumor intrinsic changes such as oncogene mutations of amplification [59]. Hence, we conducted the
Supplementary information

Conclusions
We conclude that among the Taiwanese population of glioma patients, the p53 mutant status and p53 codon 72 polymorphisms had relatively little prognostic influence in GBM patients. The bevacizumab plus CCRT treatment significantly prolongs the overall survival of GBM patients compared with the CCRT treatment alone. Relatedly, we found a significant difference in the overall survival of GBM treated with CCRT plus bevacizumab compared with GBM treated with CCRT alone that was dependent on the different p53 codon 72 genotypes, with both the Arg/Arg and Pro/Arg genotypes being associated with a better prognosis than the Pro/Pro genotype. Despite this, however, there is still no reasonable explanation for the benefits of bevacizumab treatment being connected with p553 codon 72 polymorphism variants. Nonetheless, the variants of the p53 codon 72 polymorphism are likely to worth considering as a predictive biomarker before providing bevacizumab treatment. Further studies with larger population sizes are still warranted to confirm the results of the present study.

Acknowledgements
We wish to express our appreciation to Prof. Jiunn-Liang Ko (Institute of Medicine, Chung Shan Medical University), and Dr. Shih-Lan Hsu (Department of Medical Research, Taichung Veterans General Hospital) for their valuable suggestions.

Authors’ contributions
Conception and design: WC, CS; Development of methodology: MC, YL, WH; Acquisition of data: JC, CL, XD; Analysis and interpretation of data: WC, MC, JC; Writing and review: CS; Administrative, technical, or material support: TM, GC, SC, BL. All authors have read and approved the manuscript.

Funding
This work was partly supported by grants from Taichung Veterans General Hospital; Grant number: TCYGH-1074905C, TCYGH-1084907C, TCYGH-CTUS T1087703, TCYGH-1074903B, TCYGH-HK1078004, TCYGH-1084902B, and TCYGH H-HK1088003, Taiwan. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript. None of the authors received a salary from the above funders.

Availability of data and materials
All relevant data have been uploaded to DRYAD and can be accessed using the following link: https://datadryad.org/stash/share/vlsUBjoljPS DP0baT8WmeUEjZv0NpAwWmPy7D00WcNg

Ethics approval and consent to participate
The protocols of this study were approved by the Medical Ethics Committee of Taichung Veterans General Hospital (Approval number: CF17263B-2). The obtained samples were frozen immediately after surgery with prior written consent from the patients. The validation cohort consisted of 143 cases selected from the primary cohort based on the following criteria: (1) available follow-up data and samples and (2) a post-operative survival time of more than 1 month. From January 2007 to August 2017, tissue specimens were collected from 99 patients with newly diagnosed GBM. Exclusion criteria: 1. GBM patients with unconfirmed pathology, 2. GBM patients with spinal involvement, 3. GBM patients with incomplete data records.

Consent for publication
All authors read and approved the manuscript.

Competing interests
All of the authors declare no conflicts of interest.

Author details
1Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan. 2Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung 43302, Taiwan. 3Department of Medicine, National Defense Medical Center, Taipei, Taiwan. 4Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 5Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 6Basic Medical Education, Central Taiwan University of Science and Technology, Taichung, Taiwan. 7Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. 8Department of Neurosurgery, Neurological Institute, Taichung Tzu Chi Hospital, Taichung city, Taiwan. 9Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan. 10Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 11Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. 12Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan. 13Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.

Received: 6 November 2019 Accepted: 23 July 2020

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07210-8.

Additional file 1.

Abbreviations
GBM: Glioblastoma multiforme; SNP: Single nucleotide polymorphisms; mRNA: Messenger RNA; CCRT: The concurrent chemoradiotherapy with temozolomide treatment; BPDE: Benzo[a]pyrene-7,8,9,10-diol epoxide; MDSC: Myeloid-derived suppressor cells; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism

References
1. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017; 36(28):3943–56.
2. White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016(6): a026120.
3. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.

Zhangzhou city, China. 10Department of Medical Imaging and Radiological Neurosurgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Taichung, Taiwan. 7Institute of Biomedical Sciences, National Chung Hsing University, Taichung city, Taiwan. 9Department of Defense Medical Center, Taipei, Taiwan. 5Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 8Department of Neurosurgery, Neurological Institute, Taichung Tzu Chi Hospital, Taichung city, Taiwan. 6Basic Medical Education, Central Taiwan University of Science and Technology, Taichung, Taiwan. 7Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. 8Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan. 9Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 10Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan. 11Biostatistics Task Force, Taichung Veterans General Hospital, Taichung, Taiwan.

Acknowledgements
We wish to express our appreciation to Prof. Jiunn-Liang Ko (Institute of Medicine, Chung Shan Medical University), and Dr. Shih-Lan Hsu (Department of Medical Research, Taichung Veterans General Hospital) for their valuable suggestions.

Authors’ contributions
Conception and design: WC, CS; Development of methodology: MC, YL, WH; Acquisition of data: JC, CL, XD; Analysis and interpretation of data: WC, MC, JC; Writing and review: CS; Administrative, technical, or material support: TM, GC, SC, BL. All authors have read and approved the manuscript.

Funding
This work was partly supported by grants from Taichung Veterans General Hospital; Grant number: TCYGH-1074905C, TCYGH-1084907C, TCYGH-CTUS T1087703, TCYGH-1074903B, TCYGH-HK1078004, TCYGH-1084902B, and TCYGH H-HK1088003, Taiwan. The funders had no role in the study design, data collection, and analysis, decision to publish, or preparation of the manuscript. None of the authors received a salary from the above funders.

Availability of data and materials
All relevant data have been uploaded to DRYAD and can be accessed using the following link: https://datadryad.org/stash/share/vlsUBjoljPS DP0baT8WmeUEjZv0NpAwWmPy7D00WcNg

Ethics approval and consent to participate
The protocols of this study were approved by the Medical Ethics Committee of Taichung Veterans General Hospital (Approval number: CF17263B-2). The obtained samples were frozen immediately after surgery with prior written consent from the patients. The validation cohort consisted of 143 cases selected from the primary cohort based on the following criteria: (1) available follow-up data and samples and (2) a post-operative survival time of more than 1 month. From January 2007 to August 2017, tissue specimens were collected from 99 patients with newly diagnosed GBM. Exclusion criteria: 1. GBM patients with unconfirmed pathology, 2. GBM patients with spinal involvement, 3. GBM patients with incomplete data records.

Consent for publication
All authors read and approved the manuscript.

Competing interests
All of the authors declare no conflicts of interest.

Author details
1Neurological Institute Head of Department of Neurosurgery Taichung Veterans General Hospital, Taichung, Taiwan. 2Department of Physical Therapy, Hung Kuang University, No. 1650, Taiwan Boulevard Sec. 4 Taichung 407, Taichung 43302, Taiwan. 3Department of Medicine, National Defense Medical Center, Taipei, Taiwan. 4Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 5Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 6Basic Medical Education, Central Taiwan University of Science and Technology, Taichung, Taiwan. 7Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. 8Department of Neurosurgery, Neurological Institute, Taichung Tzu Chi Hospital, Taichung city, Taiwan. 9Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan. 10Department of Game and Product Design, Chienkuo Technology University, Changhua city, Taiwan. 11Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan. 12Department of Neurosurgery, Taichung Veterans General Hospital, Taichung, Taiwan. 13Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan.

Received: 6 November 2019 Accepted: 23 July 2020

Supplementary information accompanies this paper at https://doi.org/10.1186/s12885-020-07210-8.

Additional file 1.

Abbreviations
GBM: Glioblastoma multiforme; SNP: Single nucleotide polymorphisms; mRNA: Messenger RNA; CCRT: The concurrent chemoradiotherapy with temozolomide treatment; BPDE: Benzo[a]pyrene-7,8,9,10-diol epoxide; MDSC: Myeloid-derived suppressor cells; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism

References
1. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017; 36(28):3943–56.
2. White E. Autophagy and p53. Cold Spring Harb Perspect Med. 2016(6): a026120.
3. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.
4. Yang Z, Nie S, Zhu H, Wu X, Jia S, Luo Y, Tang W. Association of p53 Arg72Pro polymorphism with bladder cancer: a meta-analysis. Gene. 2013;512(2):408–13.

5. Pettitjean A, Matte E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622–9.

6. Lin HY, Huang CH, Wu WI, Chang LC, Lung FW. TP53 codon 72 gene polymorphism paradox in associated with various carcinoma incidences, invasiveness and chemotherapy responses. Int J Biomed Sci. 2008;4(4):248–54.

7. Storey A, Thomas M, Kalita A, Hanwood C, Gardidio D, Mantovani F, Brener J, Leigh IM, Maribeshwari G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393(6682):239–44.

8. Zhao Y, Adjie AA. Targeting angiogenesis in Cancer therapy: moving beyond vascular endothelial growth factor. Oncol Lett. 2015;20(6):660–73.

9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391–400.

10. Shen CC, Cheng WY, Chiao MT, Liang YJ, Mao TF, Liu BS. Two novel hepatin-binding vascular endothelial growth factor splices, L-VEGF144 and L-VEGF138, are expressed in human Glioblastoma cells. Curr Neurovasc Res. 2016;13(3):207–18.

11. Hu Y, McDermott MP, Ahenadt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005;11(7):2502–9.

12. Zhou X, Hao Q, Lu H. Mutant p53 in Cancer Therapy - the Barrier or the Promise. J Mol Cell Biol. 2019;11(4):293–305. https://doi.org/10.1093/jmcb/mjy072.

13. de Oliveira GA, Rangel LP, Costa DC, Silva JL. Misfolding, aggregation and diseases: on the potential toxicity of p53 misfolding. Biochim Biophys Acta. 2013;1830(6):3235–44.

14. Lin HY, Huang CH, Wu WJ, Chang LC, Lung FW. TP53 codon 72 gene polymorphism, associated with age at onset of glioblastoma. Neurology. 2009;72(4):332–8.

15. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, Rodero M, Chinot O, Thillet J, et al. TP53 codon 72 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23(10):1954–6.

16. Hu Y, McDermott MP, Ahenadt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005;11(7):2502–9.

17. Zhou X, Hao Q, Lu H. Mutant p53 in Cancer Therapy - the Barrier or the Promise. J Mol Cell Biol. 2019;11(4):293–305. https://doi.org/10.1093/jmcb/mjy072.

18. Campisi G, Panzaire V, Giuliano M, Lajoie C, Di Fedo O, Falaschini S, Di Lullo C, Scully C, Lo Muzio L. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (Review). Int J Oncol. 2007;30(4):813–23.

19. Horii Y, Takahashi T, Kurishiri T, Hibi K, Sugiyama M, Niimi T, Shirakoma K, Yamakawa K, Nakamura Y, Ueda R, et al. Prognostic significance of p53 missense mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer. 1993;53(1):1–4.

20. Lowe SW, Bodis S, McClatchy A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266(5188):807–10.

21. Yu JL, Rak JW, Coombes BR, Heikin DJ, Verbol RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002;295(5559):1526–8.

22. Wu D, Zhang Z, Chu H, Xu M, Xue Y, Zhu H, Zhang Z. Introns 3 sixteen base pairs duplication polymorphism of p53 contributes to breast cancer susceptibility: evidence from meta-analysis. PLoS One. 2013;8(4):e61662.

23. Wu X, Zhao H, Amos CI, Shete S, Makani N, Hong WK, Kudlaur FP, Spritz MR. p53 genotypes and haplotypes associated with Lung Cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94(9):681–90.

24. Sæge M, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17883626). Gene. 2013;478(1):66–72.

25. Yuan G, Liu X, Liu Z, Qi M. The association between p53 codon 72 polymorphism and endometrial Cancer risk: a system review and meta-analysis. Int J Gynecol Cancer. 2016;26(5):1121–8.

26. Tang NP, Wu YM, Wang B, Ma J. Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 2010;36(5):431–8.

27. Liu Y, Liu Y, Zeng J, He Y, Peng Q, Deng Y, Wang J, Xie L, Li T, Qin X, et al. Association of p53 codon 72 polymorphism with prostate cancer: an updated meta-analysis. Tumour Biol. 2014;35(5):3997–4005.

28. Al-Qasem A, Toulimat M, Tulbah A, Elkum N, Al-Tweigeri T, Aboussekhra A. Multivariate analysis of p53 Arg72Pro polymorphism with prostate cancer: a meta-analysis. Cancer Genet Cytogenet. 2008;180(1):14–9.

29. Han J, Zhang H, Zhao X, Zhang Q, Yang Y, Li J. Association between p53 codon 72 polymorphism and cervical cancer risk among Asian: a HuGE review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(1):4003–14.

30. Min-min H, Ming-rong X, Ze-yi C, Kai-xuan Y, Zhi-lin S. Analysis of p53 codon 72 polymorphism and its association with human papillomavirus 16 and 18 E6 in Chinese cervical lesions. Int J Gynecol Cancer. 2006;16(6):2004–8.
48. Eskander EF, Abd-Rabou AA, Yahya SM, El Sherbini A, Mohamed MS, Shaker OG. P53 codon 72 single base substitution in viral hepatitis C and hepatocarcinoma incidences. Indian J Clin Biochem. 2014;29(1):3–7.

49. Hu Z, Li C, Chen K, Wang LE, Sturgis EM, Spitz MR, Wei Q. Single nucleotide polymorphisms in selected apoptotic genes and BPDE-induced apoptotic capacity in apparently Normal primary lymphocytes: a genotype-phenotype correlation analysis. J Cancer Epidemiol. 2008;2008:147905.

50. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357–65.

51. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 2008;7(12):979–87.

52. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 2004;4(10):793–805.

53. Gunaratna RT, Santos A, Luo L, Nagi C, Lambertz I, Spier M, Conti CJ, Fuchs-Young RS. Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model. Oncogene. 2019;38(18):3535–50.

54. Fujiwara M, Kohenbacht G, Fellows-Mayle W, Hamilton RL, Konohara Y, Decker SA, Chiffest JR, Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res. 2011;71(7):2664–74.

55. Sawyers CL. The cancer biomarker problem. Nature. 2008;452(7187):548–52.

56. Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Ngheimphu RL, et al. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neuro-Oncol. 2019;142(3):587–95.

57. Janning M, Muller V, Vettorazz E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Okada H. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Oncogene. 2019;38(18):3535–50.

58. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15(6):385–403.

59. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilienbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):1243–50.

60. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol. 2009;27(8):1227–34.

61. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol. 2010;28(24):3657–76.